Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Are Medical Stocks Lagging McKesson (MCK) This Year?


The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has McKesson (MCK) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

McKesson is a member of our Medical group, which includes 983 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. McKesson is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for MCK's full-year earnings has moved 1.8% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the latest available data, MCK has gained about 23.9% so far this year. Meanwhile, stocks in the Medical group have lost about 3.5% on average. As we can see, McKesson is performing better than its sector in the calendar year.

Another Medical stock, which has outperformed the sector so far this year, is Cencora (COR). The stock has returned 27.4% year-to-date.

Over the past three months, Cencora's consensus EPS estimate for the current year has increased 2.5%. The stock currently has a Zacks Rank #2 (Buy).

To break things down more, McKesson belongs to the Medical - Dental Supplies industry, a group that includes 14 individual companies and currently sits at #30 in the Zacks Industry Rank. This group has gained an average of 0.8% so far this year, so MCK is performing better in this area.

In contrast, Cencora falls under the Medical Services industry. Currently, this industry has 58 stocks and is ranked #89. Since the beginning of the year, the industry has moved -6.3%.

Investors with an interest in Medical stocks should continue to track McKesson and Cencora. These stocks will be looking to continue their solid performance.

Higher. Faster. Sooner. Buy These Stocks Now

A small number of stocks are primed for a breakout, and you have a chance to get in before they take off.

At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We’ve combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month.

You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days.

Download the report free now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
McKesson Corporation (MCK): Free Stock Analysis Report
 
Cencora, Inc. (COR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research


Source Zacks-com

Like: 0
Share
At Zacks, we are dedicated to independent investment research, helping investors succeed through tools like our Zacks Rank stock-rating system, which has averaged +23.89% annual returns since 1988. Founded on the discovery that earnings estimate revisions drive stock prices, we offer purely mathematical, unbiased ratings, along with additional innovations like the Price Response Indicator, Earnings ESP, and specialized rankings for mutual funds and ETFs.
...
Legal notice

Comments